Antolina R. M.
- Country
- Spain
- Department
- Servicio de Nefrología
Research Overview
- A Phase 2 Study to Evaluate the Safety and Tolerability of ADX-038 in Participants With Complement-Mediated Kidney Disease
- Efficacy and Safety of Oral BI 764198 in Adults and Adolescents with Primary or TRPC6-Variant Genetic Focal Segmental Glomerulosclerosis: A Randomized, Placebo-Controlled Trial
- A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN)
Data & Insights
Has run more than one trial at 61 of 177 partner sites.
Specializations
Oncology and solid tumor care
The investigator is involved in clinical research across a broad range of malignant diseases, with a strong emphasis on breast cancer, non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, and prostate cancer. The portfolio also includes gastrointestinal, gynecologic, and head and neck cancers, reflecting interest in advanced and metastatic disease settings.
- Breast cancer
- Non-small cell lung cancer
- Renal cell carcinoma
- Urothelial carcinoma
- Head and neck squamous cell carcinoma
Research activity also extends to sarcomas, ovarian cancer, gastric cancer, colorectal cancer, and other solid tumors with unmet therapeutic need.
Cardiovascular disease and thrombotic disorders
Clinical trial involvement includes a wide spectrum of cardiovascular conditions such as atherosclerotic cardiovascular disease, acute coronary syndrome, myocardial infarction, heart failure, atrial fibrillation, and hypertension. The investigator also works in prevention-oriented studies addressing vascular risk and recurrent events.
- Atherosclerotic cardiovascular disease
- Acute myocardial infarction
- Heart failure
- Atrial fibrillation
- Resistant hypertension
Additional interest is seen in stroke, venous thromboembolism, aortic stenosis, and other vascular complications linked to long-term cardiometabolic risk.
Nephrology and immune-mediated kidney disease
As part of Servicio de Nefrología, the investigator is engaged in studies of chronic kidney disease, IgA nephropathy, focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, and lupus nephritis. The research landscape also includes kidney involvement in systemic and metabolic disease.
- Chronic kidney disease
- IgA nephropathy
- Focal segmental glomerulosclerosis
- Lupus nephritis
- Complement-mediated kidney disease
Therapeutic interests extend to renal cell carcinoma and kidney-related complications in diabetes and autoimmune disease.
Neurology and neurodegenerative disease
The investigator participates in trials covering Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, migraine, and schizophrenia. This area includes both chronic neurodegenerative disorders and symptomatic neurological conditions.
- Alzheimer's disease
- Multiple sclerosis
- Epilepsy
- Migraine
- Schizophrenia
Research also touches on cognitive impairment, seizure disorders, and neuropsychiatric symptoms associated with complex neurological illness.
Respiratory, infectious, and autoimmune conditions
Clinical trial participation includes chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, asthma, pneumonia, COVID-19, and other respiratory infections. The investigator is also involved in studies of systemic lupus erythematosus, psoriasis, atopic dermatitis, and other immune-mediated disorders.
- Chronic obstructive pulmonary disease
- Idiopathic pulmonary fibrosis
- COVID-19
- Systemic lupus erythematosus
- Atopic dermatitis
Additional therapeutic interests include allergic disease, urticaria, and infectious complications requiring targeted medical intervention.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.